Navigation Links
In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study
Date:6/17/2008

g discovery, development and realization to measure the inputs and outputs of innovation during the process of bringing new products to market. The six key innovations were selected based on their impact on patient care and health outcomes: targeted therapies with companion molecular diagnostics, monoclonal antibodies (MAbs), stem cell therapy, RNA interference (RNAi), drug device combinations and radiotherapy.

Additional benchmark findings based on data from the Deloitte report indicate:

-- Targeted therapies with companion molecular diagnostics - Have quickly

progressed from idea to realization as a number of new products entered

the market in the last few years. Discovery innovation remains active

and development continues.

-- Monoclonal antibodies - Have achieved widespread clinical acceptance in

the past three years after more than 20 years of variable progress.

However, the volume of discovery innovations has dropped off as they

move into the next stage, development. New structures and methods have

resulted in a fresh set of innovations, some of which are already in

the clinic.

-- Stem cells - Have achieved a high level of discovery innovation over

the past six years; however realization and development have not yet

occurred.

-- RNAi - As a newer technology in the area of therapeutic treatment, RNAi

experienced discovery innovation only in the last four years; however,

there has been modest development and no realization yet.

-- Drug-device combinations - Have achieved general acceptance over the

past six years, and as this trend toward convergence evolves, a second

wave of innovation suggests future realization activity.

-- Radiotherapy - A relatively mature innovation, radiotherapy has

experienced a recent burst of innovation over the past three years

resulting
'/>"/>

SOURCE Deloitte
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
2. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
3. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
4. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
5. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
7. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
8. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
9. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
10. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
11. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)... Drug safety specialty firm Bio...ning and Informatics earned the Certified Professi...dential from the American Society for Training and...elle Flewell has more than fifteen years of medica...ce and is responsible for the development of the c...
(Date:11/5/2009)... Brooke Sanders brings a new lo... CA (PRWEB) November 5, 2009 -- Professional Repro...prographics company is pleased to present Brooke S... their graphics/PR specialist. The addition of Bro...tent growth within Professional Reprographics., , ...
(Date:11/4/2009)... The Human Anthrax Vaccine Prog... completed the feature film "A Call to Arms:2...mentary "Fatal Immunity: The Human Anthrax Va...lear and present danger of top secret government s...es with no accountability to its victims. It is a...
(Date:11/4/2009)...PETERSBURG, Va., Nov. 4 ...ed today that the company plans to introduce the C...bsidiary, Rock Creek Pharmaceuticals, for worldwid...iv Health, Inc . (Nasdaq: VTIV). inVentiv Health...tions for every stage of the product lifecycle, in...
Breaking Biology Technology:BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 2BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 3BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 4Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 2Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 3Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 4Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 5Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 6Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 7Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 2Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 3Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 4
... Inc. (Nasdaq and SWX: BMRN) announced today that ...idiary of Daiichi Sankyo),exclusive rights to data...TM) (sapropterin dihydrochloride) new drug applica...t its current filing to the Japanese,Ministry of H...product for,the treatment of phenylketonuria (PKU)...
...otech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: A...agreement with Johnson & Johnson,s subsidiary, Con...patent litigation with respect to Conor,s,CoStar(R...lace, Angiotech expects that the resources,require...should decrease,",said Dr. William Hunter, Preside...
... (Nasdaq: KERX ) today announced that I. Craig He... an overview of the Company,s cancer,pipeline at t... Conference,in San Francisco. Dr. Henderson,s pres...9th at 8:30 am PT. Dr. Henderson,s presentation w...e Investor Information page of the Company,s Websi...
Other Biology Technology:Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan 2Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan 3Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan 4Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation 2Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation 3Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation 4Keryx Biopharmaceuticals to Present at Bank of America Investment Conference 2
(Date:11/8/2009)...09) The loss of a gene through deletion of geneti...nificant abnormalities in learning and behavior, s...ege of Medicine ( www.bcm.edu ) in a report that a...s . , "This research goes about 95 percent of th...p of individuals to this gene," said Dr. Arthur L....
(Date:11/6/2009)...ally live in harmony with their arboreal hosts. Bu...space in their trees of choice, the ants can get d... published in the November issue of the American ...re into live trees, and it reopens a centuries-old...s. , Ants and certain species of plants and tree...
(Date:11/5/2009)...ers at Yale University have developed synthetic mo...ponse to HIV and HIV-infected cells, as well as to...online in the Journal of the American Chemical So... for these diseases. , The molecules called "a... and "antibody-recruiting molecule targeting prost...
Breaking Biology News(10 mins):Developmental delay could stem from nicotinic receptor deletion 2Ants are friendly to some trees, but not others 2New synthetic molecules trigger immune response to HIV and prostate cancer 2Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO ESMO Congress 2009 5015 1Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO ESMO Congress 2009 5015 2Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO ESMO Congress 2009 5015 3Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO ESMO Congress 2009 5015 4Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO ESMO Congress 2009 5015 5Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO ESMO Congress 2009 5015 6Save a Life 3A Join the Kiel Mortgage Marrow thon on September 23 57447 1Save a Life 3A Join the Kiel Mortgage Marrow thon on September 23 57447 2The Nations Largest Nonprofit Healthcare System Ascension Health Praises Step Forward in Health Reform Debate 57443 1The Nations Largest Nonprofit Healthcare System Ascension Health Praises Step Forward in Health Reform Debate 57443 2
...elease is available in German . , Leipzig. Fallo... are evidently capable of having a much greater ef...umed. This is the conclusion drawn by researchers ...hed fields in southern Ukraine and led to extremel...tral Europe. On 24 March 2007 the dust cloud sprea...
...of young schoolchildren from a remote Siberian vil...play at the American Association for the Advanceme...W, Washington, D.C. , The children, who are 9-14...uestions from the audience via a videoteleconferen...orium. The works, mainly watercolors and some char...
...eak of the insidious screw worm fly in Yemen, is t... livestock is a traditional way of life. In recent...n Vienna, Austria, to turn to the international co...ly pest. , The menacing fly lays its eggs in a cu...ots then feast off the living flesh, and can kill ...
Other Biology News:Arable land can have a negative impact on air quality 2Arable land can have a negative impact on air quality 3Arable land can have a negative impact on air quality 4Arable land can have a negative impact on air quality 5May 14 AAAS Lecture and videoteleconference on artworks by Siberian schoolchildren 2Screw worm outbreak in Yemen 2Screw worm outbreak in Yemen 3
Silencer Pre-designed siRNA, standard purity from Ambion
Rabbit Anti-Human Q86SZ3 Polyclonal Antibody, Unconjugated from Atlas Antibodies
Silencer Pre-designed siRNA, HPLC purified from Ambion
PCR-CleanUp Mix from Yorkshire Bioscience Ltd
Biology Products: